Cyclophosphamide, epirubicin, high-dose folinic acid and 5-fluorouracil (super-FEC) as first-line chemotherapy for advanced breast cancer: Preliminary results

Zaniboni, Alberto; Simoncini, Edda; Marpicati, P.; Montini, E; Ferrari, Vittorio; Ferragni, A; Boari, L; Marini, G

doi:10.1016/0277-5379(89)90408-2

Cited by 11 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The database contains information on patients who have been treated at this Department only. They have received chemotherapy as part of routine clinical practice or on institutional protocols; the results were published elsewhere [7, 8]. …”

Section: Methodsmentioning

confidence: 99%

A Retrospective Series of Long-Term Survivors of Metastatic Breast Cancer in Complete Remission

Amoroso¹,

Valcamonico²,

Simoncini³

et al. 2005

Oncology

Self Cite

View full text Add to dashboard Cite

Aim: To describe clinical features, treatment modalities and long-term outcome of patients with overt metastatic breast cancer in complete remission for more than 5 years. Patients and Methods: A retrospective survey of 12 patients who were referred to a single institution from 1982 to 1995. Results: The majority of the long-term survivors had a good performance status, endocrine-responsive disease and a single metastatic site. Ten patients had received chemotherapy, 8 patients hormone therapy, and 2 patients had been treated with surgery followed by systemic therapies. At a median follow-up of 11.7 years, 10 of the 12 patients were still in complete remission. The median duration of complete remission was 9.2 years (range 5.0–15.7 years). Conclusions: This case series confirms that only a few metastatic breast cancer patients could potentially be cured with multidisciplinary treatments.

show abstract

Section: Methodsmentioning

confidence: 99%

A Retrospective Series of Long-Term Survivors of Metastatic Breast Cancer in Complete Remission

Amoroso¹,

Valcamonico²,

Simoncini³

et al. 2005

Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the last decade epidoxorubicin has received EDXR and the relative toxicity. Dosages from 20-30 mg/ considerable attention by many oncologists, and it has (17,29). Hematopoietic growth factors have allowed the delivery of higher doses of chemotherapeutic agents with the aim of increasing both rate and duration response without severe and life-threatening myelosuppression (20,21).…”

Section: Radiotherapy Sixty Percent Of Patients Had Been Treatedmentioning

confidence: 99%

“…Moreover, single agent EDXR has been employed at very high dosage (120 mg/m') without unacceptable toxicity, suggesting a possible role of EDXR in the design of multidrug regimens with high dose antracycline (16). EDXR at the dose of 75-90 mg/m' has been employed as part of multidrug regimens also comprising I-FA/S-FU with or without CTX (17)(18)(19).…”

mentioning

confidence: 99%

A Phase I—II Study of Cyclophosphamide, Epidoxorubicin, Levofolinic Acid/5-Fluorouracil and Recombinant Human Granulocyte Colony Stimulating Factor in Metastatic Breast Carcinoma

Callari¹,

Gebbia

Testa

et al. 1994

Acta Oncologica

View full text Add to dashboard Cite

Alternating weekly doxorubicin and 5-fluorouracil/leucovorin followed by weekly doxorubicin and daily cyclophosphamide in stage IV breast cancer. A southwest oncology group study

Ellis

Green

Schulman

et al. 1991

Cancer

View full text Add to dashboard Cite

Twenty‐seven women with metastatic breast cancer were treated with doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH) every other week, alternating with 5‐fluorouracil (5FU) and high‐dose calcium leucovorin, for a 12‐week induction regimen, followed by weekly doxorubicin and oral daily cyclophosphamide. Twenty‐five women were eligible and evaluable. Of these, complete response occurred in two patients (8%) and partial response in six patients (24%), for a total response rate of 32%. Toxicity was similar to that seen in previous Southwest Oncology Group (SWOG) trials in this patient population. Response rates in this study were inferior, with comparable median survivals to those of previous SWOG studies that are reviewed. Additional, more dose‐intensive approaches incorporating newer approaches to the administration of cancer chemotherapeutic agents are planned.

show abstract

Cyclophosphamide, epirubicin, high-dose folinic acid and 5-fluorouracil (super-FEC) as first-line chemotherapy for advanced breast cancer: Preliminary results

Cited by 11 publications

References 15 publications

A Retrospective Series of Long-Term Survivors of Metastatic Breast Cancer in Complete Remission

A Retrospective Series of Long-Term Survivors of Metastatic Breast Cancer in Complete Remission

A Phase I—II Study of Cyclophosphamide, Epidoxorubicin, Levofolinic Acid/5-Fluorouracil and Recombinant Human Granulocyte Colony Stimulating Factor in Metastatic Breast Carcinoma

Alternating weekly doxorubicin and 5-fluorouracil/leucovorin followed by weekly doxorubicin and daily cyclophosphamide in stage IV breast cancer. A southwest oncology group study

Contact Info

Product

Resources

About